Ann: September 2023 Quarterly Update and Appendix 4C, page-7

Prescient ended the quarter with cash reserves of $18.7 million ($21.8 million on 30 June 2023) of which
$16 million was held in term deposits with maturities of between six and 12 months. Net operating
expenditure during the quarter was $3.2 million, in line with budget. A total of $2.4 million was invested
in R&D and clinical development activities.

The business is operating with a cash runway of 5.9 quarters based on net cash used during the quarter,
however, Prescient expects the actual cash runway to extend beyond this.